临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 145-13-1

Pregnenolone

中文名称:孕烯醇酮
CAS号:145-13-1
分子式: C21H32O2 分子量: 316.48
产品形式: free base
研发状态: Recruiting
研发用途: Alcohol Use Disorder
研究机构: Yale University; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
研发日期: January 8 2024
研发阶段: Phase 2
Pregnenolone(3β-Hydroxy-5-pregnen-20-one) is an endogenous steroid hormone, used in the treatment of fatigue, Alzheimer’s disease, trauma and injuries.

CAS: 145108-58-3

Dexmedetomidine HCl

中文名称:盐酸右美托咪啶
CAS号:145108-58-3
分子式: C13H16N2.HCl 分子量: 236.74
产品形式: HCl
研发状态: Unknown status
研发用途: Postoperative Shivering; Cesarean Delivery
研究机构: Rehman Medical Institute - RMI
研发日期: February 1 2022
研发阶段: Phase 4
Dexmedetomidine HCl((+)-Medetomidine Hydrochloride) is a highly selective and potent alpha-2 adrenoceptor agonist, which reduces anesthetic requirements for patients by providing significant sedation.

CAS: 1450833-55-2

TAK-243 (MLN7243)

CAS号:1450833-55-2
分子式: C19H20F3N5O5S2 分子量: 519.52
产品形式: Free base
研发状态: Not yet recruiting
研发用途: Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelomonocytic Leukemia; Refractory High Risk Myelodysplastic Syndrome
研究机构: National Cancer Institute (NCI)
研发日期: August 30 2024
研发阶段: Phase 1
TAK-243 (MLN7243) is a potent, mechanism-based small-molecule inhibitor of the ubiquitin activating enzyme (UAE) with an IC50 of 1 ± 0.2 nM in the UBCH10 E2 thioester assay. It has minimal inhibitory activity in a panel of kinase and receptor assays, as well as on human carbonic anhydrase type I and type II. TAK-243 (MLN7243) induces ER stress, abrogates NFκB pathway activation and promotes apoptosis.

CAS: 145040-37-5

Candesartan Cilexetil

中文名称:坎地沙坦酯
CAS号:145040-37-5
分子式: C33H34N6O6 分子量: 610.66
产品形式: free base
研发状态: Unknown status
研发用途: Healthy Male Subjects
研究机构: Ahn-Gook Pharmaceuticals Co.Ltd
研发日期: Nov-15
研发阶段: Phase 1
Candesartan Cilexetil (TCV-116) is an angiotensin II receptor antagonist with IC50 of 0.26 nM, used in the treatment of hypertension.

CAS: 144875-48-9

Resiquimod (R-848)

中文名称:雷西莫特
CAS号:144875-48-9
分子式: C17H22N4O2 分子量: 314.38
产品形式: free base
研发状态: Recruiting
研发用途: Innate Inflammatory Response; Asthma; Nasal Allergy
研究机构: Cambridge University Hospitals NHS Foundation Trust
研发日期: August 9 2022
研发阶段: Not Applicable
Resiquimod (R-848, S28463) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. Resiquimod reduces hepatitis C virus (HCV) infection. Phase 2.

CAS: 1448671-31-5

AZD3965

中文名称:(S)-5-(4-羟基-4-甲基异恶唑烷-2-羰基)-1-异丙基-3-甲基-6-((5-甲基-3-(三氟甲基)-1H-吡唑-4-基)甲基)噻吩并[2,3-D]嘧啶-2,4(1H,3H)-二酮
CAS号:1448671-31-5
分子式: C21H24F3N5O5S 分子量: 515.51
产品形式: free base
研发状态: Completed
研发用途: Adult Solid Tumor; Diffuse Large B Cell Lymphoma; Burkitt Lymphoma
研究机构: Cancer Research UK; AstraZeneca
研发日期: April 23 2013
研发阶段: Phase 1
AZD3965 is a potent, selective and orally available monocarboxylate transporter 1 (MCT1) inhibitor with a binding affinity of 1.6 nM, 6-fold selective over MCT2. Phase 1.